Clinical Trial

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-26.
Status change: Not Yet Recruiting → Recruiting 2026-04-03
Trial Details
NCT Number NCT06573411
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Conditions Primary Membranous Nephropathy
Enrollment 116 participants
Start Date 2024-09-30
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08